Abstract: Embodiments of the present invention relate to use of a GP73 inhibitor in preparation of a drug for treating diabetes. In the embodiments of the present invention, the inventor finds that GP73 plays a key role in blood glucose regulation, and in particular, finds that soluble GP73 can specifically bind to glucagon to form a complex, enhances the blood glucose-rising function and gluconeogenesis function of glucagon and prolongs the half-life of glucagon; and finds soluble GP73 can activate the glucose production in liver and/or kidney and a gluconeogenesis signaling pathway in a glucagon-independent manner. Based on the blood glucose regulation effect of the GP73 described above, the inventor also proves through animal experiments: the GP73 inhibitor can reduce the blood glucose level and glycated hemoglobin level of diabetic mice and have a protective effect on islet ? cells, and thereby having the effect of treating diabetes.

Abstract: The present invention provides a lectin-magnetic carrier coupling complex for separating glycosylated exosomes from a clinical sample. The lectin-magnetic carrier coupling complex comprises a magnetic carrier and lectins coupled to the outer side of the magnetic carrier. The lectin-magnetic carrier coupling complex provided by the present invention may rapidly, accurately, and automatically separate glycosylated exosomes from a clinical sample with a high separation efficiency; and the separated exosomes are intact in morphology without rupturing or cracking, may be directly used for liquid detection of glycosylated exosomes, or directly used for immunology-related detection, or directly used for nucleotide sequence detection and analysis after extracting nucleic acids from the exosomes.

Abstract: The present invention relates to a lectin-macromolecular carrier coupling complex for separating glycosylated exosomes from a clinical sample, which comprises a macromolecular carrier and lectins coupled to the outer side of the macromolecular carrier. The complex may simply, conveniently, rapidly, and accurately separate glycosylated exosomes from a clinical sample with a high separation efficiency and a good repeatability; and the separated exosomes are intact in morphology without rupturing or cracking, may be directly used for liquid detection of glycosylated exosomes, or directly used for immunology-related detection, or directly used for gene detection or analysis after extracting related nucleic acids from the exosomes.